CN104602676A - 包含非马沙坦和氢氯噻嗪的药物组合物 - Google Patents

包含非马沙坦和氢氯噻嗪的药物组合物 Download PDF

Info

Publication number
CN104602676A
CN104602676A CN201380040573.0A CN201380040573A CN104602676A CN 104602676 A CN104602676 A CN 104602676A CN 201380040573 A CN201380040573 A CN 201380040573A CN 104602676 A CN104602676 A CN 104602676A
Authority
CN
China
Prior art keywords
pharmaceutical composition
hydrochlorothiazide
fimasartan
prepared
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380040573.0A
Other languages
English (en)
Chinese (zh)
Inventor
金济学
南京完
朴敍薰
金周元
金相烨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boryung Pharmaceutical Co Ltd
Original Assignee
Boryung Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104602676(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharmaceutical Co Ltd filed Critical Boryung Pharmaceutical Co Ltd
Priority to CN201910766865.1A priority Critical patent/CN110496122A/zh
Publication of CN104602676A publication Critical patent/CN104602676A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380040573.0A 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物 Pending CN104602676A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910766865.1A CN110496122A (zh) 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120070359A KR101414873B1 (ko) 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
KR10-2012-0070359 2012-06-28
PCT/KR2013/003734 WO2014003305A1 (ko) 2012-06-28 2013-04-30 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910766865.1A Division CN110496122A (zh) 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物

Publications (1)

Publication Number Publication Date
CN104602676A true CN104602676A (zh) 2015-05-06

Family

ID=49783403

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380040573.0A Pending CN104602676A (zh) 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物
CN201910766865.1A Pending CN110496122A (zh) 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910766865.1A Pending CN110496122A (zh) 2012-06-28 2013-04-30 包含非马沙坦和氢氯噻嗪的药物组合物

Country Status (21)

Country Link
US (1) US9457094B2 (cg-RX-API-DMAC7.html)
EP (1) EP2868316B1 (cg-RX-API-DMAC7.html)
JP (1) JP6145506B2 (cg-RX-API-DMAC7.html)
KR (1) KR101414873B1 (cg-RX-API-DMAC7.html)
CN (2) CN104602676A (cg-RX-API-DMAC7.html)
AU (1) AU2013281582B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014032764B1 (cg-RX-API-DMAC7.html)
CA (1) CA2877444C (cg-RX-API-DMAC7.html)
CL (1) CL2014003525A1 (cg-RX-API-DMAC7.html)
CO (1) CO7240413A2 (cg-RX-API-DMAC7.html)
ES (1) ES2654207T3 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00645A (cg-RX-API-DMAC7.html)
MX (1) MX351521B (cg-RX-API-DMAC7.html)
MY (1) MY165075A (cg-RX-API-DMAC7.html)
PE (1) PE20150607A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502876B1 (cg-RX-API-DMAC7.html)
RU (1) RU2613900C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201408666SA (cg-RX-API-DMAC7.html)
UA (1) UA111434C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014003305A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409508B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111405893A (zh) * 2017-11-30 2020-07-10 保宁制药株式会社 含有非马沙坦的药物组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
KR102233673B1 (ko) * 2016-01-27 2021-03-30 보령제약 주식회사 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
SG11201806292QA (en) * 2016-01-27 2018-08-30 Boryung Pharmaceutical Co Ltd Pharmaceutical composition for preventing or treating diabetic nephropathy
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR20220162456A (ko) * 2021-06-01 2022-12-08 주식회사 보령 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN120037195B (zh) * 2023-09-28 2025-11-28 浙江百代医药科技有限公司 一种硫辛酸药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
IL162754A0 (en) * 2002-01-16 2005-11-20 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereof
EP2029112B2 (en) 2006-06-16 2014-02-19 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
EP2203158A4 (en) * 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-n-부틸-4-히드록시-6-메틸-피리미딘-5-일)-N,N-디메틸아세트아미드의 신규한 제조방법
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
CN102397278A (zh) * 2010-09-19 2012-04-04 鲁南制药集团股份有限公司 一种抗高血压药物组合物
CN102485227B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102485228B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102058602B (zh) * 2010-12-21 2013-04-10 中国药科大学 一种稳定的含氯沙坦钾和氢氯噻嗪的口服固体制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEON ET AL.: "Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers", <<JOURNAL OF CARDIOVASCULAR PHARMACOLOGY>>, vol. 59, no. 1, 31 January 2012 (2012-01-31), pages 85, XP008175979 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111405893A (zh) * 2017-11-30 2020-07-10 保宁制药株式会社 含有非马沙坦的药物组合物

Also Published As

Publication number Publication date
MX351521B (es) 2017-10-18
CO7240413A2 (es) 2015-04-17
ZA201409508B (en) 2016-08-31
MY165075A (en) 2018-02-28
WO2014003305A1 (ko) 2014-01-03
CA2877444C (en) 2017-08-01
AU2013281582B2 (en) 2016-06-09
RU2613900C2 (ru) 2017-03-21
CA2877444A1 (en) 2014-01-03
SG11201408666SA (en) 2015-03-30
BR112014032764B1 (pt) 2021-12-07
UA111434C2 (uk) 2016-04-25
PH12014502876A1 (en) 2015-02-23
PH12014502876B1 (en) 2015-02-23
JP2015525745A (ja) 2015-09-07
MX2014015841A (es) 2015-07-17
EP2868316B1 (en) 2017-12-06
EP2868316A1 (en) 2015-05-06
BR112014032764A2 (pt) 2017-06-27
JP6145506B2 (ja) 2017-06-14
KR20140006233A (ko) 2014-01-16
PE20150607A1 (es) 2015-05-16
US9457094B2 (en) 2016-10-04
RU2015102553A (ru) 2016-08-20
ES2654207T3 (es) 2018-02-12
EP2868316A4 (en) 2016-02-17
KR101414873B1 (ko) 2014-07-03
CN110496122A (zh) 2019-11-26
IN2015DN00645A (cg-RX-API-DMAC7.html) 2015-06-26
CL2014003525A1 (es) 2015-04-10
AU2013281582A1 (en) 2015-02-05
US20150147394A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CA2877444C (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
TWI325318B (en) Capsule and method of manufacturing the same
CN106232144B (zh) 固体分散体
EP1985310A1 (en) Solid dosage forms
CN101327213B (zh) 厄贝沙坦氢氯噻嗪药用组合物及其制备方法
CN119700772A (zh) Tyk2抑制剂的延长释放剂型
KR20180104125A (ko) 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
EP2293781A1 (en) Granulation of active pharmaceutical ingredients
JP2023549763A (ja) 複素環式化合物を含む組成物、その製造方法と応用
US10583087B2 (en) Pharmaceutical composition for oral administration
MX2014007331A (es) Sistema de multiunidades de granulos de liberacion inmediata.
JP2017523149A (ja) エドキサバンの医薬組成物
CN105434386B (zh) 一种含有高水溶性活性成分的缓释片剂及其制备方法
CN104271134B (zh) 含有5-羟基-1h-咪唑-4-甲酰胺的片剂
CN102137664A (zh) 具有被边界隔开的有效成分的固体药物制剂
CN103768068A (zh) 一种波生坦药物组合物
CN106456612A (zh) 经口给药用医药组合物
HK40119663A (en) Dosage forms for tyk2 inhibitors
HK40119662A (en) Dosage forms for tyk2 inhibitors
HK40119664A (zh) Tyk2抑制剂的剂型
TR2021001943A2 (tr) Emoksi̇pi̇n i̇çeren bi̇r fi̇lm kapli tablet
HK1224221B (en) Solid preparation comprising tofogliflozin and method for producing same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150506